Evgen Pharma : Appointment of Chief Medical Officer

Evgen (AIM: EVG), a clinical stage drug development company focused on the treatment of cancer, inflammation and acute respiratory distress syndrome, announces that Glen Clack, MD, FFPM will be joining the Company as Chief Medical Officer effective from 1 May 2021.

Dr Clack has over 30 years' experience in oncology and translational medicine, and held various roles within AstraZeneca for almost 20 years. Dr Clack has specialised in early phase oncology clinical development with an emphasis on a number of important cancers and has a wealth of experience in conducting and managing clinical trials. He has successfully provided strategic and operational leadership from Phase I through to regulatory submissions and commercialisation. He has been a lead member of study, clinical development and project teams on multiple trials.

Glen is an Honorary Professor of Translational Medicine at the University of Sheffield and an MSc Module Tutor and Honorary Lecturer in Translational Science at the University of Manchester. He has an MB BS from the Royal Free Hospital School of Medicine in London, is a Fellow of the Faculty of Pharmaceutical Medicine at the University of Wales and holds an MD from the University of Sheffield.

Dr Huw Jones CEO of Evgen commented: 'We are delighted to have someone of Glen's experience and knowledge join our team. As we progress further with our clinical programmes, Glen's depth of understanding in the fields where we are active will be invaluable. Glen will also be a key member of the team involved in leveraging our relationships with our many partners. His unique skillset has seen him take responsibility for a number of large, complex projects and he has published over 50 academic papers on various cancers.'

Contact:

Evgen Pharma plc

Barry Clare

Chairman

Richard Moulson

CFO

Website: www.evgen.com

FinnCap

Corporate Finance

Geoff Nash

Teddy Whiley

Website: www.finncap.com

T: [phone]

Alice Lane (ECM)

Walbrook PR

T: [phone]

E: [e-mail]

Paul McManus

T: [phone]

Anna Dunphy

T: [phone]

About Evgen Pharma plc

Evgen Pharma is a clinical stage drug development company developing sulforaphane based medicines for the treatment of multiple diseases.?The Company's core technology is Sulforadex, a method for synthesising and stabilising the naturally occurring compound sulforaphane and novel proprietary analogues based on sulforaphane.?The lead product, SFX-01, is a patented composition of synthetic sulforaphane and alpha-cyclodextrin.

Clinical data from the Company's open-label Phase II STEM trial has shown that SFX-01 can halt the growth of progressing tumours in patients with oestrogen-positive (ER+) metastatic breast cancer, and in some cases significantly shrink the tumour, whilst causing very few side effects.

The Company commenced operations in January 2008 and has its headquarters at Alderley Park, Cheshire, and its registered office is at the Liverpool Science Park,?Liverpool.??It is listed on the AIM market of the London Stock Exchange and trades under the ticker symbol EVG.?

For further information, please visit: www.evgen.com

For research on the Company, please visit: http://evgen.com/investors/analyst-coverage/

(C) 2021 Electronic News Publishing, source ENP Newswire